Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients

Tamura, Masaya; Sakurai, Hideyuki; Mizumoto, Masashi; Kamizawa, Satoshi; Murayama, Shigeyuki; Yamashita, Haruo; Takao, Seishin; Suzuki, Ryusuke; Shirato, Hiroki; Ito, Yoichi M.

Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients

Tamura, Masaya; Sakurai, Hideyuki; Mizumoto, Masashi et al.

Journal of Radiation Research, 2017, 58(3), 363-371

Permalink : https://hdl.handle.net/2115/67159

このアイテムのアクセス数:1,604件（2026-08-08 18:33 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JRadiatRes58_363	pdf	349 KB	562

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/67159
タイトル	Lifetime attributable risk of radiation-induced secondary cancer from proton beam therapy compared with that of intensity-modulated X-ray therapy in randomly sampled pediatric cancer patients
著者	Tamura, Masaya ; Sakurai, Hideyuki ; Mizumoto, Masashi ; Kamizawa, Satoshi ; Murayama, Shigeyuki ; Yamashita, Haruo ; Takao, Seishin ; Suzuki, Ryusuke ; Shirato, Hiroki ; Ito, Yoichi M.
著者名 Tamura, Masaya
著者名 Sakurai, Hideyuki
著者名 Mizumoto, Masashi
著者名 Kamizawa, Satoshi
著者名 Murayama, Shigeyuki
著者名 Yamashita, Haruo
e-Rad_Researcher 10614216 著者名 Takao, Seishin
e-Rad_Researcher 00400052 著者名 Suzuki, Ryusuke
e-Rad_Researcher 20187537 著者名 Shirato, Hiroki
e-Rad_Researcher 10334236 著者名 Ito, Yoichi M.
言語	英語
キーワード	radiation-induced
	secondary cancer
	proton beam therapy
	intensity-modulated radiotherapy
	lifetime attributable risk
発行日	2017-05
出版者	Oxford University Press
収録物名	Journal of Radiation Research
巻(号)	58(3)
ページ	363-371
抄録	To investigate the amount that radiation-induced secondary cancer would be reduced by using proton beam therapy (PBT) in place of intensity-modulated X-ray therapy (IMXT) in pediatric patients, we analyzed lifetime attributable risk (LAR) as an in silico surrogate marker of the secondary cancer after these treatments. From 242 pediatric patients with cancers who were treated with PBT, 26 patients were selected by random sampling after stratification into four categories: (i) brain, head and neck, (ii) thoracic, (iii) abdominal, and (iv) whole craniospinal (WCNS) irradiation. IMXT was replanned using the same computed tomography and region of interest. Using the dose-volume histograms (DVHs) of PBT and IMXT, the LARs of Schneider et al. were calculated for the same patient. All the published dose-response models were tested for the organs at risk. Calculation of the LARs of PBT and IMXT based on the DVHs was feasible for all patients. The means +/- standard deviations of the cumulative LAR difference between PBT and IMXT for the four categories were (i) 1.02 +/- 0.52% (n = 7, P = 0.0021), (ii) 23.3 +/- 17.2% (n = 8, P = 0.0065), (iii) 16.6 +/- 19.9% (n = 8, P = 0.0497) and (iv) 50.0 +/- 21.1% (n = 3, P = 0.0274), respectively (one tailed t-test). The numbers needed to treat (NNT) were (i) 98.0, (ii) 4.3, (iii) 6.0 and (iv) 2.0 for WCNS, respectively. In pediatric patients who had undergone PBT, the LAR of PBT was significantly lower than the LAR of IMXT estimated by in silico modeling. Although a validation study is required, it is suggested that the LAR would be useful as an in silico surrogate marker of secondary cancer induced by different radiotherapy techniques.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	0449-3060
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1093/jrr/rrw088